Fortunately, substantial progress has been made after major advances in our understanding of the biology of ER+/HER2– breast cancer in the past 20 years, such as the development of CDK4/6 inhibitors, mTOR inhibitors, PI3Kα inhibitors and histone deacetylase inhibitors [57]. This evidence concerns the gene ESR1 and breast cancer.